Last A$0.04 AUD
Change Today 0.00 / 0.00%
Volume 1.2M
PRR On Other Exchanges
As of 1:10 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - A$0.07
52 Week Low
11/14/13 - A$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Total Annual Compensation: A$364.4K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Immutep, S.A., Prima Biomed Ltd. - M&A Call

To discuss the company's recent acquisition of Immutep SA

Prima Biomed Ltd. Reports Preliminary Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Prima Biomed Ltd. reported preliminary audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported total other income was AUD 3,140,066 against AUD 4,005,394 a year ago. Loss before income tax expense was AUD 13,329,774 against AUD 15,138,798 a year ago. Loss for the year is attributable to owners of the company was AUD 13,343,381 against AUD 15,225,671 a year ago. Basic and diluted loss per share was 1.09 cents against 1.42 cents a year ago. Net cash outflow from operating activities was AUD 14,227,161 against AUD 16,037,126 a year ago. Payments for plant and equipment were AUD 103,675 against AUD 507,924 a year ago. This decrease was essentially due to lower foreign exchange gains and less interest income being earned during fiscal year 2014 (AUD 406,628 in fiscal year 2014 against AUD 1,417,613 in fiscal year 2013).

Prima Biomed Ltd. Announces Executive Changes

The Board of Prima Biomed Ltd. announced that Marc Voigt has been appointed as Chief Executive Officer of Prima. Mr. Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the company's European Operations, replaces US based Matthew Lehman who will step down from the Board but remain as an adviser to the company to facilitate an orderly transition. Following his appointment as CEO, Marc Voigt will join the Prima Board as an Executive Director. Marc has more than 16 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.04 AUD 0.00

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at